Comparison · NCT01877915-deaths
Rivaroxaban vs Placebo: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Rivaroxaban vs Placebo: deaths from any cause. Trial comparisons, record NCT01877915-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01877915-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.225 | 0.209 | 0.242 | wilson | |
| Risk in group 2 | 0.227 | 0.211 | 0.244 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00167 | -0.0248 | 0.0215 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.993 | 0.896 | 1.1 | log | |
| Odds ratio, group 1 over group 2 | 0.991 | 0.868 | 1.13 | log | |
| Number needed to treat, for one fewer death from any cause on Rivaroxaban than on Placebo | 599 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Rivaroxaban | Participants received 2.5 milligram (mg) tablet of rivaroxaban orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician). | 565 | 2,507 | EG000 |
| Group 2 | Placebo | Participants received matching placebo orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician). | 571 | 2,515 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Up to 54 Months
Source ClinicalTrials.gov
Trial
- Title
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
- NCT number
- NCT01877915
- Phases
- PHASE3
- Conditions
- Heart Failure, Coronary Artery Disease
- Interventions
- Rivaroxaban, Placebo, Standard of care for heart failure and coronary artery disease
- Lead sponsor
- Janssen Research & Development, LLC
- Results first posted
- 2019-05-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01877915?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01877915-deaths